Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other stocks under $10 that will triple.

As we delve into the discussion on stocks that will triple, we must shed light on the U.S. small-cap stocks, which are struggling amid broader market challenges due to ongoing shifts in tariff policy, affecting investors’ confidence. The Russell index (which tracks small-cap stocks) has fallen over 15% from its peak in November 2024 as of the time of writing this article and is down by nearly 19% on a YTD basis. However, the broader market, mostly consisting of large-cap stocks, has only dropped about 14% on a YTD basis. This gap shows how economic uncertainties and higher interest rates have more impact on smaller companies as they typically carry more debt and feel borrowing costs more acutely.

Furthermore, trade tensions have added to small-cap stocks’ volatility. Reuters reported that Trump’s new 25% tariffs on Canadian, Mexican, and Chinese imports rolled out on March 4, with more duties to be imposed by April 2. This measure affects nearly $2.2 trillion in trade and has sparked retaliatory tariffs from Canada and China, which have stoked inflation fears and triggered global market drops. As such, small-cap companies with international supply chains now face higher costs that could damage their profitability.

Yet, small-cap stocks might bounce back as Trump’s domestic economic growth agenda could benefit these U.S.-based companies. In addition, onshoring and increased capital expenditures (CAPEX) might boost the sector’s earnings. Furthermore, analysts believe that stabilizing inflation and easing interest rates could help small-caps recover in the second half of 2025.

As such, inflation seems to be leveling off, which is beneficial for small-cap companies. While high rates have pressured these debt-reliant companies, the Federal Reserve’s decision to slow rate hikes in late 2024 provided some breathing room. With inflation settling between 1% and 3%—historically complimentary for small-caps—the sector’s performance is expected to get a boost. Therefore, as financial market trends are settling, analysts expect small-cap earnings to outpace large-cap in 2025, especially later in the year.

A significant move that could be helpful for small-cap stocks is the recovery in mergers and acquisitions (M&A) and initial public offerings (IPOs). Even though deal activity slowed during recession fears, M&A rebounded in 2024 and is expected to continue in 2025. Historically, rising M&A activity has boosted returns across market caps and proven to be beneficial for small-caps, as it makes those companies acquisition targets, increasing investors’ interest.

Moreover, industry changes and technological advances offer more opportunities to small-cap companies. While the AI boom has mostly helped mega-cap tech industries, many smaller companies are crucial to AI infrastructure in terms of cybersecurity and thermal management. A 2023 PwC report valued the healthcare AI market at $11 billion, projecting its growth to $188 billion by 2030.

Despite the market challenges, some small-caps under $10 have beaten the broader market, showing resilience amid inflation and trade uncertainties. They show remarkable growth possibilities even as conditions fluctuate.

Methodology

We chose consensus picks of credible websites and compiled a list of stocks priced at $10 or less that are expected to triple. Furthermore, we used a screener to identify stocks with a projected upside potential of over 300%. We have also assessed the hedge fund sentiment from Insider Monkey’s database of over 1,000 elite hedge funds tracked as of the end of the fourth quarter of 2024. The list is arranged in ascending order of the number of hedge fund holders in each stock.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Upside Potential: 406.94%

Number Of Hedge Funds: 44

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial biotech company with a focus on autologous tumor-infiltrating lymphocyte (TIL) therapies. These therapies target metastatic melanoma and other solid tumor cancers. The company’s pipeline includes Amtagvi, an FDA-approved T-cell therapy for advanced melanoma, and Proleukin, an interleukin-2 product used to treat cancer. Iovance is pushing forward with lifileucel and LN-145 for non-small cell lung cancer and gynecological cancers, along with next-gen TIL therapies in clinical trials.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) showed solid performance in 2024 as its total product revenue hit $164.1 million, reaching the top end of its guidance. Amtagvi brought in $103.6 million, showing strong early adoption, while Proleukin added another $60.5 million. In Q4 alone, revenue was $73.7 million, with Amtagvi accounting for $48.7 million. For 2025, the company predicts product revenue between $450-475 million, driven by higher demand, more treatment centers, and continuous adoption.

Furthermore, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is growing globally as regulatory filings for Amtagvi are under review in the U.K., EU, and Canada, with approvals expected in 2025. The company is also running clinical trials for advanced melanoma and certain lung cancers that have not responded to immunotherapy, which could expand Amtagvi’s potential uses. Additionally, the company’s cell therapy plant expansion will soon support over 5,000 patients yearly.

Thus, with an expanded revenue base, market reach, and solid clinical progress, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ranks among the stocks that will triple.

Overall, IOVA ranks 2nd on our list of stocks under $10 that will triple. While we acknowledge the potential of IOVA, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than IOVA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.